Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Turin – page 39

677 clinical trials in Turin, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Turin at a glance
677
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

677 trials in Turin

Open in trial search

Mantle cell lymphoma recurrent+1

Not recruiting

Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Fondazione Italiana Linfomi Ets

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Amyotrophic lateral sclerosis+2

Not recruiting

Study of Tofersen for Adults with Presymptomatic Amyotrophic Lateral Sclerosis (ALS) Due to SOD1 Gene Mutation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tofersen
  • Sponsor:Biogen Idec Research Limited

Hidradenitis

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Iodide
  • Sponsor:Faraday Pharmaceuticals Inc.

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Hypercholesterolaemia

Not recruiting

Study on the Safety and Efficacy of MK-0616 for Adults with High Cholesterol

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide Chloride
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Turin

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and breast cancer treatments. Studies include evaluation of targeted therapies and immunotherapy approaches for various stages of disease.

  • Triple-negative breast cancer treatments
  • Advanced urothelial cancer therapy
  • Novel lymphoma interventions

Several trials are investigating combination therapies and maintenance treatments to improve patient outcomes.

02 Transplant Medicine

Research centered on improving outcomes in kidney transplantation, with particular focus on preventing delayed graft function and optimizing post-transplant care.

  • Graft function optimization
  • Novel immunosuppressive approaches
  • Post-transplant complications

Studies aim to enhance transplant success rates and reduce complications in organ recipients.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Crohn's Disease and pyoderma gangrenosum. Studies evaluate new biological therapies and combination treatments.

  • Inflammatory bowel disease management
  • Skin condition treatments
  • Novel therapeutic combinations

Focus on developing targeted treatments to improve disease control and patient quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.